STELLAR-304: a phase III study of zanzalintinib (XL092) plus nivolumab in advanced non-clear cell renal cell carcinoma

Pal, Sumanta; Kanesvaran, Ravindran; Molina-Cerrillo, Javier; Feldman, Darren; Barata, Pedro; Powles, Thomas; Suárez, Cristina

dc.contributor	Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author	Pal, Sumanta
dc.contributor.author	Kanesvaran, Ravindran
dc.contributor.author	Molina-Cerrillo, Javier
dc.contributor.author	Feldman, Darren
dc.contributor.author	Barata, Pedro
dc.contributor.author	Powles, Thomas
dc.contributor.author	Suárez, Cristina
dc.date.accessioned	2025-04-02T12:56:24Z
dc.date.available	2025-04-02T12:56:24Z
dc.date.issued	2025-02-26
dc.identifier.citation	Pal SK, Powles T, Kanesvaran R, Molina-Cerrillo J, Feldman DR, Barata P, et al. STELLAR-304: a phase III study of zanzalintinib (XL092) plus nivolumab in advanced non-clear cell renal cell carcinoma. Futur Oncol. 2025 Feb 26;21(7):787-94.
dc.identifier.issn	1744-8301
dc.identifier.uri	http://hdl.handle.net/11351/12887
dc.description	Inhibidor del punto de control inmunitario; Carcinoma renal de células no claras; Inhibidor de la tirosina quinasa
dc.language.iso	eng
dc.publisher	Taylor & Francis
dc.relation.ispartofseries	Future Oncology;21(7)
dc.rights	Attribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.source	Scientia
dc.subject	Ronyons - Càncer - Tractament
dc.subject	Quimioteràpia combinada
dc.subject	Anticossos monoclonals - Ús terapèutic
dc.subject	Proteïnes quinases - Inhibidors - Ús terapèutic
dc.subject.mesh	Antineoplastic Combined Chemotherapy Protocols
dc.subject.mesh	Carcinoma, Renal Cell
dc.subject.mesh	Protein Kinase Inhibitors
dc.subject.mesh	/antagonists & inhibitors
dc.subject.mesh	Antibodies, Monoclonal
dc.subject.mesh	/therapeutic use
dc.subject.mesh	Carcinoma, Renal Cell
dc.subject.mesh	/drug therapy
dc.title	STELLAR-304: a phase III study of zanzalintinib (XL092) plus nivolumab in advanced non-clear cell renal cell carcinoma
dc.type	info:eu-repo/semantics/article
dc.identifier.doi	10.1080/14796694.2025.2458395
dc.subject.decs	protocolos de quimioterapia antineoplásica combinada
dc.subject.decs	inhibidores de proteínas cinasas
dc.subject.decs	/antagonistas & inhibidores
dc.subject.decs	anticuerpos monoclonales
dc.subject.decs	/uso terapéutico
dc.subject.decs	carcinoma de células renales
dc.subject.decs	/farmacoterapia
dc.relation.publishversion	https://doi.org/10.1080/14796694.2025.2458395
dc.type.version	info:eu-repo/semantics/publishedVersion
dc.audience	Professionals
dc.contributor.organismes	Institut Català de la Salut
dc.contributor.authoraffiliation	[Pal SA] Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA. [Powles T] Department of Genitourinary Oncology, Barts Health NHS Trust Saint Bartholomew’s Hospital, London, UK. [Kanesvaran R] Division of Medical Oncology, National Cancer Centre Singapore, Singapore. [Molina-Cerrillo J] Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain. [Feldman DR] Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. [Barata P] Department of Medicine, University Hospitals Seidman Cancer Center, Cleveland, OH, USA. [Suarez C] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain
dc.identifier.pmid	40008409
dc.identifier.wos	001433380500001
dc.rights.accessrights	info:eu-repo/semantics/openAccess